115 related articles for article (PubMed ID: 38244401)
21. miR-423-5p Inhibits Osteosarcoma Proliferation and Invasion Through Directly Targeting STMN1.
Wang X; Peng L; Gong X; Zhang X; Sun R; Du J
Cell Physiol Biochem; 2018; 50(6):2249-2259. PubMed ID: 30423576
[TBL] [Abstract][Full Text] [Related]
22. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer.
Hemdan T; Lindén M; Lind SB; Namuduri AV; Sjöstedt E; de Ståhl TD; Asplund A; Malmström PU; Segersten U
Br J Cancer; 2014 Sep; 111(6):1180-7. PubMed ID: 25072257
[TBL] [Abstract][Full Text] [Related]
24. Stathmin1 overexpression in hypopharyngeal squamous cell carcinoma: A new promoter in FaDu cell proliferation and migration.
Chen Y; Zhang Q; Ding C; Zhang X; Qiu X; Zhang Z
Int J Oncol; 2017 Jan; 50(1):31-40. PubMed ID: 27878293
[TBL] [Abstract][Full Text] [Related]
25. STMN1 overexpression correlates with biological behavior in human cutaneous squamous cell carcinoma.
Li X; Wang L; Li T; You B; Shan Y; Shi S; Qian L; Cao X
Pathol Res Pract; 2015 Nov; 211(11):816-23. PubMed ID: 26235036
[TBL] [Abstract][Full Text] [Related]
26. An Immunohistochemical Study of Stathmin 1 Expression in Osteosarcoma Shows an Association with Metastases and Poor Patient Prognosis.
Zhao C; Li H; Wang L; Sun W
Med Sci Monit; 2018 Aug; 24():6070-6078. PubMed ID: 30169496
[TBL] [Abstract][Full Text] [Related]
27. Stathmin 1 promotes the progression of liver cancer through interacting with YAP1.
Liu YP; Pan LL; Kong CC
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7335-7344. PubMed ID: 32706072
[TBL] [Abstract][Full Text] [Related]
28. STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway.
Jiang W; Huang S; Song L; Wang Z
Oncol Rep; 2018 Feb; 39(2):834-842. PubMed ID: 29251330
[TBL] [Abstract][Full Text] [Related]
29. Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma.
He X; Liao Y; Lu W; Xu G; Tong H; Ke J; Wan X
Tumour Biol; 2016 Jul; 37(7):9951-8. PubMed ID: 26815505
[TBL] [Abstract][Full Text] [Related]
30. Expression of Stathmin1 in gastric adenocarcinoma.
Batsaikhan BE; Yoshikawa K; Kurita N; Iwata T; Takasu C; Kashihara H; Shimada M
Anticancer Res; 2014 Aug; 34(8):4217-21. PubMed ID: 25075050
[TBL] [Abstract][Full Text] [Related]
31. Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients.
Obayashi S; Horiguchi J; Higuchi T; Katayama A; Handa T; Altan B; Bai T; Bao P; Bao H; Yokobori T; Nishiyama M; Oyama T; Kuwano H
Int J Oncol; 2017 Sep; 51(3):781-790. PubMed ID: 28766688
[TBL] [Abstract][Full Text] [Related]
32. Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment.
Wu W; Tan XF; Tan HT; Lim TK; Chung MC
Mol Cancer Res; 2014 Dec; 12(12):1717-28. PubMed ID: 25063586
[TBL] [Abstract][Full Text] [Related]
33. Stathmin is overexpressed in malignant mesothelioma.
Kim JY; Harvard C; You L; Xu Z; Kuchenbecker K; Baehner R; Jablons D
Anticancer Res; 2007; 27(1A):39-44. PubMed ID: 17352214
[TBL] [Abstract][Full Text] [Related]
34. Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma.
Wang S; Akhtar J; Wang Z
Tumour Biol; 2015 Sep; 36(10):7797-806. PubMed ID: 25944168
[TBL] [Abstract][Full Text] [Related]
35. A preliminary study: is fibulin 1 a friend or an enemy that needs to be silenced with siRNAs for mesothelioma?
Aksoy A; Tektemur A; Melek E; Kayfeci M; Uslu MF; Cosar U; Onalan E
Contemp Oncol (Pozn); 2020; 24(4):241-246. PubMed ID: 33531871
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of Stathmin 1 correlates with poor prognosis and promotes cell migration and proliferation in oesophageal squamous cell carcinoma.
Ni PZ; He JZ; Wu ZY; Ji X; Chen LQ; Xu XE; Liao LD; Wu JY; Li EM; Xu LY
Oncol Rep; 2017 Dec; 38(6):3608-3618. PubMed ID: 29039594
[TBL] [Abstract][Full Text] [Related]
37. Elevated STMN1 Expression Correlates with Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.
Li J; Hu G; Kong F; Wu K; Song K; He J; Sun W
Pathol Oncol Res; 2015 Sep; 21(4):1013-20. PubMed ID: 25791566
[TBL] [Abstract][Full Text] [Related]
38. Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients.
Kuang XY; Chen L; Zhang ZJ; Liu YR; Zheng YZ; Ling H; Qiao F; Li S; Hu X; Shao ZM
Oncotarget; 2015 Sep; 6(26):22227-38. PubMed ID: 26087399
[TBL] [Abstract][Full Text] [Related]
39. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
[TBL] [Abstract][Full Text] [Related]
40. MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1.
Wang R; Wang HB; Hao CJ; Cui Y; Han XC; Hu Y; Li FF; Xia HF; Ma X
PLoS One; 2012; 7(10):e46173. PubMed ID: 23071542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
